Acumen Pharmaceuticals (ABOS)

• Market cap: $155M
• 1 day: -0.92%
• 5 days: -1.83%
• 1 month: -19.48%
• 3 months: -10.04%
• 6 months: -16.99%
• Year to date: 6.44%
• 1 year: 53.57%
• 5 years: -85.92%
• 10 years: -89.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Employees: 61